The Therapeutic Potential of Rosemary (Rosmarinus officinalis) Diterpenes for Alzheimer's Disease

Evidence-based Complementary and Alternative Medicine

Volumn 2016, Issue , 2016, Pages

  Habtemariam, Solomon ^a  

^a Herbal Analysis Services UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; DITERPENE; METAL; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN; CHELATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; ETHNOPHARMACOLOGY; HERBAL MEDICINE; HUMAN; MEMORY; NEUROPROTECTION; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; REVIEW; ROSEMARY; SPECIES DIVERSITY;

EID: 84958213859     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2016/2680409     Document Type: Review

References (179)

1. Food Standards Agency, "Current EU approved additives and their E Numbers," https://www.food.gov.uk/science/additives/enumberlist.
2. B. Bozin, N. Mimica-Dukic, I. Samojlik, and E. Jovin, "Antimicrobial and antioxidant properties of rosemary and sage (Rosmarinus officinalis L. and Salvia officinalisL., Lamiaceae) essential oils," Journal of Agricultural and Food Chemistry,vol.55,no. 19, pp. 7879-7885, 2007.
3. S. Cheung and J. Tai, "Anti-proliferative and antioxidant properties of rosemary Rosmarinus officinalis," Oncology Reports, vol. 17,no. 6, pp. 1525-1531, 2007.
4. O. Yesil-Celiktas, C. Sevimli, E. Bedir, and F. Vardar-Sukan, "Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines," Plant Foods for Human Nutrition, vol. 65, no. 2, pp. 158-163, 2010.
5. T. Bakirel, U. Bakirel, O. Ü. Keleş, S. G. Ülgen, and H. Yardibi, "In vivo assessment of antidiabetic and antioxidant activities of rosemary (Rosmarinus officinalis) in alloxan-diabetic rabbits," Journal of Ethnopharmacology, vol. 116, no. 1, pp. 64-73, 2008.
6. M. E. González-Trujano, E. I. Peña, A. L. Martínez et al., "Evaluation of the antinociceptive effect of Rosmarinus officinalis L. using three different experimental models in rodents," Journal of Ethnopharmacology, vol. 111, no. 3, pp. 476-482, 2007.
7. G. A. Nogueira de Melo, R. Grespan, J. P. Fonseca et al., "Rosmarinus officinalis L. essential oil inhibits in vivo and in vitro leukocyte migration," Journal of Medicinal Food, vol. 14, no. 9, pp. 944-949, 2011.
8. M. Estévez, R. Ramírez, S. Ventanas, and R. Cava, "Sage and rosemary essential oils versus BHT for the inhibition of lipid oxidative reactions in liver pâté," LWT - Food Science and Technology, vol. 40, no. 1, pp. 58-65, 2007.
9. P.-F. Laura, M. T. Garzón, and M. Vicente, "Relationship between the antioxidant capacity and effect of rosemary (Rosmarinus officinalis L.) polyphenols on membrane phospholipid order," Journal of Agricultural and Food Chemistry, vol. 58, no. 1, pp. 161-171, 2010.
10. J. Yamamoto, K. Yamada, A. Naemura, T. Yamashita, and R. Arai, "Testing various herbs for antithrombotic effect," Nutrition, vol. 21, no. 5, pp. 580-587, 2005.
11. I. Gülçin, Ö. I. Küfrevioʇlu, M. Oktay, and M. E. Büyükokuroʇlu, "Antioxidant, antimicrobial, antiulcer and analgesic activities of nettle (Urtica dioica L.)," Journal of Ethnopharmacology, vol. 90, no. 2-3, pp. 205-215, 2004.
12. P. Corrêa Dias, M. A. Foglio, A. Possenti, and J. E. De Carvalho, "Antiulcerogenic activity of crude hydroalcoholic extract of Rosmarinus officinalis L.," Journal of Ethnopharmacology, vol. 69, no. 1, pp. 57-62, 2000.
13. D. O. Kennedy and A. B. Scholey, "The psychopharmacology of European herbs with cognition-enhancing properties," Current Pharmaceutical Design, vol. 12, no. 35, pp. 4613-4623, 2006.
14. M. Haloui, L. Louedec, J.-B. Michel, and B. Lyoussi, "Experimental diuretic effects of Rosmarinus officinalis and Centaurium erythraea," Journal of Ethnopharmacology, vol. 71, no. 3, pp. 465-472, 2000.
15. K. G. E.-D. Abdel-Wahhab, K. A. El-Shamy, N. A. E.-Z. El-Beih, F. A. Morcy, and F. A. E. Mannaa, "Protective effect of a natural herb (Rosmarinus officinalis) against hepatotoxicity in male albino rats," Comunicata Scientiae, vol. 2, no. 1, pp. 9-17, 2011.
16. 4-induced acute liver damage in rats," European Journal of Gastroenterology & Hepatology, vol. 14, no. 9, pp. 1001-1006, 2002.
17. A. C. Atti-Santos, M. Rossato, G. F. Pauletti et al., "Physicochemical evaluation of Rosmarinus officinalis L. essential oils," Brazilian Archives of Biology and Technology, vol. 48, no. 6, pp. 1035-1039, 2005.
18. O. Touafek, A. Nacer, A. Kabouche et al., "Chemical composition of the essential oil of Rosmarinus officinalis cultived in the Algerian Sahara," Chemistry of Natural Compounds, vol. 40, no. 1, pp. 28-29, 2004.
19. L. Valgimigli, Essential Oils As Natural Food Additives: Composition, Applications, Antioxidant and Antimicrobial Properties, Nova Science Publishers, New York, NY, USA, 2012.
20. S. Djeddi, N. Bouchenah, I. Settar, and H. D. Skaltsa, "Composition and antimicrobial activity of the essential oil of Rosmarinus officinalis from Algeria," Chemistry of Natural Compounds,vol. 43, no. 4, pp. 487-490, 2007.
21. S. I. Dimitrijević, K. R. Mihajlovski, D. G. Antonović, M. R. Milanović-Stevanović, and D. Ž. Mijin, "A study of the synergistic antilisterial effects of a sub-lethal dose of lactic acid and essential oils from Thymus vulgaris L., Rosmarinus officinalis L. and Origanum vulgare L.," Food Chemistry, vol. 104, no. 2, pp. 774-782, 2007.
22. L. Gachkar, D. Yadegari, M. B. Rezaei, M. Taghizadeh, S. A. Astaneh, and I. Rasooli, "Chemical and biological characteristics of Cuminum cyminum and Rosmarinus officinalis essential oils," Food Chemistry, vol. 102, no. 3, pp. 898-904, 2007.
23. E. Issabeagloo, P. Kermanizadeh, and R. T. Forughi, "Antimicrobial effects of rosemary (Rosmarinus officinalis L.) essential oil against Staphylococcus spp.," African Journal of Microbiology Research, vol. 6, no. 23, pp. 5039-5042, 2012.
24. A. M. Ojeda-Sana, C. M. van Baren, M. A. Elechosa, M. A. Juárez, and S. Moreno, "New insights into antibacterial and antioxidant activities of rosemary essential oils and their main components," Food Control, vol. 31, no. 1, pp. 189-195, 2013.
25. Y. Zaouali, T. Bouzaine, and M. Boussaid, "Essential oils composition in two Rosmarinus officinalis L. varieties and incidence for antimicrobial and antioxidant activities," Food and Chemical Toxicology, vol. 48, no. 11, pp. 3144-3152, 2010.
26. K. C. Başer and G. Buchbauer, Handbook of Essential Oils: Science, Technology, and Applications, CRC Press, Taylor & Francis Group, New York, NY, USA, 2010.
27. N. Bai, K. He, M. Roller et al., "Flavonoids and phenolic compounds from Rosmarinus officinalis," Journal of Agricultural and Food Chemistry, vol. 58, no. 9, pp. 5363-5367, 2010.
28. M. J. Del Baño, J. Lorente, J. Castillo et al., "Flavonoid distribution during the development of leaves, flowers, stems, and roots of Rosmarinus officinalis. Postulation of a biosynthetic pathway," Journal of Agricultural and Food Chemistry, vol. 52, no. 16, pp. 4987-4992, 2004.
29. N. Okamura, H. Haraguchi, K. Hashimoto, and A. Yagi, "Flavonoids in Rosmarinus officinalis leaves," Phytochemistry, vol. 37, no. 5, pp. 1463-1466, 1994.
30. Alzheimer's Society UK, "Alzheimers Disease. Demography," October 2015, http://www.alzheimers.org.uk/site/scripts/documents-info.php?documentID=412.
31. Alzheimer's Association, October 2015, http://www.alz.org/facts/.
32. M. Wortmann, "Dementia: a global health priority - highlights from an ADI and World Health Organization report," Alzheimer's Research and Therapy, vol. 4, no. 5, article 40, 2012.
33. J. L. Cummings and C. Back, "The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease," The American Journal of Geriatric Psychiatry, vol. 6, no. 2, supplement 1, pp. S64-S78, 1998.
34. P. J. Whitehouse, D. L. Price, R. G. Struble, A. W. Clark, J. T. Coyle, and M. R. DeLong, "Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain," Science, vol. 215, no. 4537, pp. 1237-1239, 1982.
35. R. Raschetti, E. Albanese, N. Vanacore, and M. Maggini, "Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials," PLoS Medicine, vol. 4, no. 11, pp. 1818-1828, 2007.
36. K. Brückner, D. Božić, D. Manzano et al., "Characterization of two genes for the biosynthesis of abietane-type diterpenes in rosemary (Rosmarinus officinalis) glandular trichomes," Phytochemistry, vol. 101, pp. 52-64, 2014.
37. S. Habtemariam, A. I. Gray, C. Lavaud et al., "ent-12-Oxolabda-8,13(16)-dien-15-oic acid and ent-8β,12α-epidioxy-12β-hydroxylabda-9(11),13-dien-15-oic acid γ-lactone: two new diterpenes from the aerial parts of Premna oligotricha," Journal of the Chemical Society, Perkin Transactions 1, no. 4, pp. 893-896, 1991.
38. S. Habtemariam, A. I. Gray, and P. G. Waterman, "Antibacterial diterpenes from the aerial parts of Premna oligotricha," Planta Medica, vol. 58, no. 1, pp. 109-110, 1992.
39. S. Habtemariam, "Cytotoxicity of diterpenes from Premna schimperi and Premna oligotricha," Planta Medica, vol. 61, no. 4, pp. 368-369, 1995.
40. S. Habtemariam, "In vitro antileishmanial effects of antibacterial diterpenes from two Ethiopian Premna species: P. schimperi and P. oligotricha," BMC Pharmacology, vol. 3, article 6, 2003.
41. E. Wenkert, A. Fuchs, and J. D. Mcchesney, "Chemical artifacts from the family Labiatae," Journal of Organic Chemistry, vol. 30, no. 9, pp. 2931-2934, 1965.
42. P. J. Hidalgo, J. L. Ubera, M. T. Tena, and M. Valcárcel, "Determination of the carnosic acid content in wild and cultivated Rosmarinus officinalis," Journal of Agricultural and Food Chemistry,vol. 46, no. 7, pp. 2624-2627, 1998.
43. K. Kosaka, J. Mimura, K. Itoh et al., "Role of Nrf2 and p62/ZIP in the neurite outgrowth by carnosic acid in PC12h cells," Journal of Biochemistry, vol. 147, no. 1, pp. 73-81, 2010.
44. S. Munné-Bosch and L. Alegre, "Subcellular compartmentation of the diterpene carnosic acid and its derivatives in the leaves of rosemary," Plant Physiology, vol. 125, no. 2,pp. 1094-1102, 2001.
45. S. Munné-Bosch, L. Alegre, and K. Schwarz, "The formation of phenolic diterpenes in Rosmarinus officinalis L. under Mediterranean climate," European Food Research and Technology, vol. 210, no. 4, pp. 263-267, 2000.
46. T. Tounekti and S. Munné-Bosch, "Enhanced phenolic diterpenes antioxidant levels through non-transgenic approaches," Critical Reviews in Plant Sciences, vol. 31, no. 6, pp. 505-519, 2012.
47. C. R. L. Wellwood and R. A. Cole, "Relevance of carnosic acid concentrations to the selection of rosemary, Rosmarinus officinalis (L.), accessions for optimization of antioxidant yield," Journal of Agricultural and Food Chemistry, vol. 52, no. 20, pp. 6101-6107, 2004.
48. S. Birtić, P. Dussort, F.-X. Pierre, A. C. Bily, and M. Roller, "Carnosic acid," Phytochemistry, vol. 115, pp.9-19, 2015.
49. S. Habtemariam and G. K. Varghese, "A novel diterpene skeleton: identification of a highly aromatic, cytotoxic and antioxidant 5-methyl-10-demethyl-abietane-type diterpene from Premna serratifolia," Phytotherapy Research, vol. 29, no. 1, pp. 80-85, 2015.
50. K. Schwarz and W. Ternes, "Antioxidative constituents of Rosmarinus officinalis and Salvia officinalis - II. Isolation of carnosic acid and formation of other phenolic diterpenes," Zeitschrift für Lebensmittel-Untersuchung und Forschung, vol. 195, no. 2, pp. 99-103, 1992.
51. M. Arisawa, T. Hayashi, K. Ohmura et al., "Chemical and pharmaceutical studies on medicinal plants in Paraguay: studies on 'Romero,' part 2," Journal of Natural Products, vol. 50, no. 6, pp. 1164-1166, 1987.
52. M. Takenaka, T. Watanabe, K. Sugahara, Y. Harada, S. Yoshida, and F. Sugawara, "New antimicrobial substances against Streptomyces scabies from Rosemary (Rosmarinus officinalis L.)," Bioscience, Biotechnology and Biochemistry, vol. 61, no. 9, pp. 1440-1444, 1997.
53. M.-E. Cuvelier, H. Richard, and C. Berset, "Antioxidative activity and phenolic composition of pilot-plant and commercial extracts of sage and rosemary," Journal of the American Oil Chemists' Society, vol. 73, no. 5, pp. 645-652, 1996.
54. Y. Zhang, T. A. Adelakun, L. Qu et al., "New terpenoid glycosides obtained from Rosmarinus officinalis L. aerial parts," Fitoterapia, vol. 99, pp. 78-85, 2014.
55. J. G. Luis, W. Quinones, T. A. Grillo, and M. P. Kishi, "Diterpenes from the aerial part of Salvia columbariae," Phytochemistry, vol. 35, no. 5, pp. 1373-1374, 1994.
56. N. Nakatani and R. Inatani, "A new diterpene lactone, rosmadial, from Rosemary (Rosmarinus officinalis L.)," Agricultural and Biological Chemistry, vol. 47, no. 2, pp. 353-358, 1983.
57. N. Nakatani and R. Inatani, "Two antioxidative diterpenes from Rosemary (Rosmarinus officinalis L.) and a revised structure for rosmanol," Agricultural and Biological Chemistry, vol. 48, no. 8, pp. 2081-2085, 1984.
58. J. G. Luis, "Chemistry, biogenesis and chemotaxonomy of the diterpenoids of Salvia," in Ecological Chemistry and Biochemistry of Plant Terpenoids, J. B. Marborne, Ed., pp. 63-82, Clarendon Press, Oxford, UK, 1991.
59. Y. Jiang, N. Wu, Y.-J. Fu et al., "Chemical composition and antimicrobial activity of the essential oil of Rosemary," Environmental Toxicology and Pharmacology, vol. 32, no. 1, pp. 63-68, 2011.
60. A. A. Mahmoud, S. S. Al-Shihry, and B. W. Son, "Diterpenoid quinones from Rosemary (Rosmarinus officinalis L.)," Phytochemistry, vol. 66, no. 14, pp. 1685-1690, 2005.
61. C. M. Houlihan, C.-T. Ho, and S. S. Chang, "The structure of rosmariquinone - a new antioxidant isolated from Rosmarinus officinalis L.," Journal of the American Oil Chemists' Society, vol. 62, no. 1, pp. 96-98, 1985.
62. P. C. Santos-Gomes, R. M. Seabra, P. B. Andrade, and M. Fernandes-Ferreira, "Determination of phenolic antioxidant compounds produced by calli and cell suspensions of sage (Salvia officinalis L.)," Journal of Plant Physiology, vol. 160, no. 9, pp. 1025-1032, 2003.
63. M. J. Del Baño, J. Lorente, J. Castillo et al., "Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of Rosmarinus officinalis. Antioxidant activity," Journal of Agricultural and Food Chemistry, vol. 51, no. 15, pp. 4247-4253, 2003.
64. E. N. Frankel, S.-W. Huang, R. Aeschbach, and E. Prior, "Antioxidant activity of a rosemary extract and its constituents, carnosic acid carnosol and rosmarinic acid in bulk oil and oilin-water emulsion," Journal of Agricultural and Food Chemistry, vol. 44, no. 1, pp. 131-135, 1996.
65. E. H. A. Doolaege, K. Raes, F. De Vos, R. Verhé, and S. De Smet, "Absorption, distribution and elimination of carnosic acid, a natural antioxidant from Rosmarinus officinalis, in rats," Plant Foods for Human Nutrition, vol. 66, no. 2, pp. 196-202, 2011.
66. M. R. Vaquero, R. G. Villalba, M. Larrosa et al., "Bioavailability of the major bioactive diterpenoids in a rosemary extract: metabolic profile in the intestine, liver, plasma, and brain of Zucker rats," Molecular Nutrition & Food Research, vol. 57, no. 10, pp. 1834-1846, 2013.
67. A. V. Ferlemi, A. Katsikoudi, V. G. Kontogianni et al., "Rosemary tea consumption results to anxiolytic- and anti-depressant-like behavior of adult male mice and inhibits all cerebral area and liver cholinesterase activity; phytochemical investigation and in silico studies," Chemico-Biological Interactions, vol. 237, pp. 47-57, 2015.
68. D. G. MacHado, M. P. Cunha, V. B. Neis et al., "Rosmarinus officinalis L. hydroalcoholic extract, similar to fluoxetine, reverses depressive-like behavior without altering learning deficit in olfactory bulbectomized mice," Journal of Ethnopharmacology, vol. 143, no. 1, pp. 158-169, 2012.
69. D. Zhang, B. Lee, A. Nutter et al., "Protection from cyanideinduced brain injury by the Nrf2 transcriptional activator carnosic acid," Journal of Neurochemistry, vol. 133, no. 6, pp. 898-908, 2015.
70. S.-J. Kim, J.-S. Kim, H.-S. Cho et al., "Carnosol, a component of rosemary (Rosmarinus officinalis L.) protects nigral dopaminergic neuronal cells," NeuroReport, vol. 17, no. 16, pp. 1729-1733, 2006.
71. M. Moss and L. Oliver, "Plasma 1,8-cineole correlates with cognitive performance following exposure to rosemary essential oil aroma," Therapeutic Advances in Psychopharmacology, vol. 2, no. 3, pp. 103-113, 2012.
72. M. Ozarowski, P. L. Mikolajczak, A. Bogacz et al., "Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain," Fitoterapia, vol. 91, pp. 261-271, 2013.
73. S. S. K. Wijeratne and S. L. Cuppett, "Potential of rosemary (Rosemarinus officinalis L.) diterpenes in preventing lipid hydroperoxide-mediated oxidative stress in Caco-2 cells," Journal of Agricultural and Food Chemistry, vol. 55, no. 4, pp. 1193-1199, 2007.
74. H. Haraguchi, T. Saito, N. Okamura, and A. Yagi, "Inhibition of lipid peroxidation and superoxide generation by diterpenoids from Rosmarinus officinalis," Planta Medica, vol. 61, no. 4, pp. 333-336, 1995.
75. C.-W. Hou, Y.-T. Lin, Y.-L. Chen et al., "Neuroprotective effects of carnosic acid on neuronal cells under ischemic and hypoxic stress," Nutritional Neuroscience, vol. 15, no. 6, pp. 257-263, 2012.
76. T. Satoh, M. Izumi, Y. Inukai et al., "Carnosic acid protects neuronal HT22 Cells through activation of the antioxidant-responsive element in free carboxylic acid- and catechol hydroxyl moieties-dependent manners," Neuroscience Letters, vol. 434, no. 3, pp. 260-265, 2008.
77. T. Masuda, Y. Inaba, and Y. Takeda, "Antioxidant mechanism of carnosic acid: structural identification of two oxidation products," Journal of Agricultural and Food Chemistry, vol. 49, no. 11, pp. 5560-5565, 2001.
78. S. Habtemariam, "Investigation into the antioxidant and antidiabetic potential of Moringa stenopetala: identification of the active principles," Natural Product Communications, vol. 10, no. 3, pp. 475-478, 2015.
79. S. Habtemariam and G. K. Varghese, "Extractability of rutin in herbal tea preparations of Moringa stenopetala leaves," Beverages, vol. 1, no. 3, pp. 169-182, 2015.
80. S. Habtemariam and G. K. Varghese, "The antidiabetic therapeutic potential of dietary polyphenols," Current Pharmaceutical Biotechnology, vol. 15, no. 4, pp. 391-400, 2014.
81. M. Roselli, G. Lentini, and S. Habtemariam, "Phytochemical, antioxidant and anti-α-glucosidase activity evaluations of Bergenia cordifolia," Phytotherapy Research, vol. 26, no. 6, pp. 908-914, 2012.
82. S. Habtemariam, "Methyl-3-O-methyl gallate and gallic acid from the leaves of Peltiphyllum peltatum: isolation and comparative antioxidant, prooxidant, and cytotoxic effects in neuronal cells," Journal of Medicinal Food, vol. 14, no. 11, pp. 1412-1418, 2011.
83. M. Juan-Badaturuge, S. Habtemariam, and M. J. K. Thomas, "Antioxidant compounds from a South Asian beverage and medicinal plant, Cassia auriculata," Food Chemistry,vol.125,no. 1, pp. 221-225, 2011.
84. M. Juan-Badaturuge, S. Habtemariam, C. Jackson, and M. J. K. Thomas, "Antioxidant principles of Tanacetum vulgare L. aerial parts," Natural Product Communications, vol. 4, no. 11, pp. 1561-1564, 2009.
85. S. Habtemariam and E. Dagne, "Comparative antioxidant, prooxidant and cytotoxic activity of sigmoidin A and eriodictyol," Planta Medica,vol .76, no. 6, pp. 589-594, 2010.
86. S. Habtemariam and C. Jackson, "Antioxidant and cytoprotective activity of leaves of Peltiphyllum peltatum (Torr.) Engl.," Food Chemistry, vol. 105, no. 2, pp. 498-503, 2007.
87. S. Habtemariam, "Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-α in L-929 tumor cells," Journal of Natural Products,vol. 60, no. 8, pp. 775-778, 1997.
88. S. Habtemariam, "Modulation of tumour necrosis factor-α-induced cytotoxicity by polyphenols," Phytotherapy Research, vol. 11, no. 4, pp. 277-280, 1997.
89. S. Habtemariam, "Catechols and quercetin reduce MTT through iron ions: a possible artefact in cell viability assays," Phytotherapy Research, vol. 9, no. 8, pp. 603-605, 1995.
90. S. L. Richheimer, D. T. Bailey, M. W. Bernart et al., "Antioxidant activity and oxidative degradation of phenolic compounds isolated from rosemary," in Recent Research Developments in Oil Chemistry, vol. 3, pp. 45-58, 1999.
91. K. Itoh, T. Chiba, S. Takahashi et al., "An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements," Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 313-322, 1997.
92. J. Alam, D. Stewart, C. Touchard, S. Boinapally, A. M. K. Choi, and J. L. Cook, "Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene," The Journal of Biological Chemistry, vol. 274, no. 37, pp. 26071-26078, 1999.
93. M. McMahon, K. Itoh, M. Yamamoto et al., "The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes," Cancer Research, vol. 61, no. 8, pp. 3299-3307, 2001.
94. T. Nguyen, C. S. Yang, and C. B. Pickett, "The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress," Free Radical Biology and Medicine, vol. 37, no. 4, pp. 433-441, 2004.
95. T. Satoh, K. Kosaka, K. Itoh et al., "Carnosic acid, a catecholtype electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1," Journal of Neurochemistry, vol. 104, no. 4, pp. 1116-1131, 2008.
96. K. Itoh, K. I. Tong, and M. Yamamoto, "Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles," Free Radical Biology and Medicine, vol. 36, no. 10, pp. 1208-1213, 2004.
97. T. Satoh and S. A. Lipton, "Redox regulation of neuronal survival mediated by electrophilic compounds," Trends in Neurosciences, vol. 30, no. 1, pp. 37-45, 2007.
98. T. Satoh, S.-I. Okamoto, J. Cui et al., "Activation of the Keap1/ Nrf2 pathway for neuroprotection by electrophillic phase II inducers," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 3, pp. 768-773, 2006.
99. T. Satoh, S. R. McKercher, and S. A. Lipton, "Nrf2/AREmediated antioxidant actions of pro-electrophilic drugs," Free Radical Biology and Medicine, vol. 65, pp. 645-657, 2013.
100. D. Martin, A. I. Rojo, M. Salinas et al., "Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol," The Journal of Biological Chemistry, vol. 279, no. 10, pp. 8919-8929, 2004.
101. E. Heiss, C. Herhaus, K. Klimo, H. Bartsch, and C. Gerhauser, "Nuclear factor-kappa B is a molecular target for sulforaphanemediated anti-inflammatory mechanisms," The Journal of Biological Chemistry, vol. 276, no. 34, pp. 32008-32015, 2001.
102. A. Rossi, P. Kapahi, G. Natoli et al., "Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase," Nature, vol. 403, no. 6765, pp. 103-108, 2000.
103. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subuni," The Journal of Biological Chemistry, vol. 276, no. 38, pp. 35530-35536, 2001.
104. Q. Xiang, Y. Wang, W. Wu et al., "Carnosic acid protects against ROS/RNS-induced protein damage and upregulates HO-1 expression in RAW264.7 macrophages," Journal of Functional Foods, vol. 5, no. 1, pp. 362-369, 2013.
105. K. W. Singletary, "Rosemary extract and carnosol stimulate rat liver glutathione-S-transferase and quinone reductase activities," Cancer Letters, vol. 100, no. 1-2, pp. 139-144, 1996.
106. D. A. Butterfield, J. Drake, C. Pocernich, and A. Castegna, "Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide," Trends in Molecular Medicine, vol. 7,no. 12, pp. 548-554, 2001.
107. C. Pereira, P. Agostinho, P. I. Moreira, S. M. Cardoso, and C. R. Oliveira, "Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies," Current Drug Target - CNS & Neurological Disorders, vol. 4, no. 4, pp. 383-403, 2005.
108. B. Halliwell, "Oxidative stress and neurodegeneration: where are we now?" Journal of Neurochemistry, vol. 97, no. 6, pp. 1634-1658, 2006.
109. S. C. Dyall and A. T. Michael-Titus, "Neurological benefits of omega-3 fatty acids," NeuroMolecular Medicine, vol. 10, no. 4, pp. 219-235, 2008.
110. 2-induced neuronal apoptosis," Journal of Neurochemistry, vol. 73, no. 3, pp. 1181-1188, 1999.
111. S. Asha Devi, "Aging brain: prevention of oxidative stress by vitaminEandexercise,"TheScientificWorldJOURNAL, vol. 9, pp. 366-372, 2009.
112. K. Murakami, N. Murata, Y. Noda et al., "SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease," The Journal of Biological Chemistry, vol. 286, no. 52, pp. 44557-44568, 2011.
113. P. Bermejo, S. Martín-Aragón, J. Benedí et al., "Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from mild cognitive impairment," Free Radical Research, vol. 42, no. 2, pp. 162-170, 2008.
114. H. Liu, H. Wang, S. Shenvi, T. M. Hagen, and R.-M. Liu, "Glutathione metabolism during aging and in Alzheimer disease," Annals of the New York Academy of Sciences, vol. 1019, pp. 346-349, 2004.
115. P. I. Moreira, C. Carvalho, X. Zhu, M. A. Smith, and G. Perry, "Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology," Biochimicaa et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1802, no. 1, pp. 2-10, 2010.
116. J. Dong, C. S. Atwood, V. E. Anderson et al., "Metal binding and oxidation of amyloid-β within isolated senile plaque cores: raman microscopic evidence," Biochemistry, vol. 42, no. 10, pp. 2768-2773, 2003.
117. I. Grundke-Iqbal, J. Fleming, Y.-C. Tung, H. Lassmann, K. Iqbal, and J. G. Joshi, "Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia," Acta Neuropathologica, vol. 81, no. 2, pp. 105-110, 1990.
118. M. A. Lovell, J. D. Robertson, W. J. Teesdale, J. L. Campbell, and W. R. Markesbery, "Copper, iron and zinc in Alzheimer's disease senile plaques," Journal of the Neurological Sciences, vol. 158, no. 1, pp. 47-52, 1998.
119. H. Tamano and A. Takeda, "Dynamic action of neurometals at the synapse," Metallomics, vol. 3, no. 7, pp. 656-661, 2011.
120. Z. Hui-Hui, T. Peng-Fei, Z. Kan, W. Hui, W. Bao-Huai, and L. Jing-Fen, "Antioxidant properties of phenolic diterpenes from Rosmarinus officinalis," Acta Pharmacologica Sinica, vol. 22, no. 12, pp. 1094-1098, 2001.
121. S. Samman, B. Sandström, M. B. Toft et al., "Green tea or rosemary extract added to foods reduces nonheme-iron absorption," The American Journal of Clinical Nutrition, vol. 73, no. 3, pp. 607-612, 2001.
122. X.-L. Chen, G. Dodd, S. Thomas et al., "Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression," American Journal of Physiology - Heart and Circulatory Physiology, vol. 290, no. 5, pp. H1862-H1870, 2006.
123. M. H. Kapturczak, C. Wasserfall, T. Brusko et al., "Hemeoxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse," The American Journal of Pathology, vol. 165, no. 3, pp. 1045-1053, 2004.
124. K.-C. Lian, J.-J. Chuang, C.-W. Hsieh et al., "Dual mechanisms of NF-κB inhibition in carnosol-treated endothelial cells," Toxicology and Applied Pharmacology, vol. 245, no. 1, pp. 21-35, 2010.
125. H. Yao, Y. Chen, L. Zhang et al., "Carnosol inhibits cell adhesion molecules and chemokine expression by tumor necrosis factor-α in human umbilical vein endothelial cells through the nuclear factor-κB and mitogen-activated protein kinase pathways," Molecular Medicine Reports, vol. 9, no. 2, pp. 476-480, 2014.
126. R. Foresti, S. K. Bains, T. S. Pitchumony et al., "Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells," Pharmacological Research, vol. 76, pp. 132-148, 2013.
127. Y.-M. Yu, C.-H. Lin, H.-C. Chan, and H.-D. Tsai, "Carnosic acid reduces cytokine-induced adhesion molecules expression and monocyte adhesion to endothelial cells," European Journal of Nutrition, vol. 48, no. 2, pp. 101-106, 2009.
128. Q. Xiang, Z. Liu, Y. Wang et al., "Carnosic acid attenuates lipopolysaccharide-induced liver injury in rats via fortifying cellular antioxidant defense system," Food and Chemical Toxicology, vol. 53, pp. 1-9, 2013.
129. D. Poeckel, C. Greiner, M. Verhoff et al., "Carnosic acid and carnosol potently inhibit human 5-lipoxygenase and suppress pro-inflammatory responses of stimulated human polymorphonuclear leukocytes," Biochemical Pharmacology, vol. 76, no. 1, pp. 91-97, 2008.
130. A.-H. Lo, Y.-C. Liang, S.-Y. Lin-Shiau, C.-T. Ho, and J.-K. Lin, "Carnosol, an antioxidant in rosemary, suppresses inducible nitric oxide synthase through down-regulating nuclear factor-κB in mouse macrophages," Carcinogenesis, vol. 23, no. 6, pp. 983-991, 2002.
131. M. Yanagitai, S. Itoh, T. Kitagawa, T. Takenouchi, H. Kitani, and T. Satoh, "Carnosic acid, a pro-electrophilic compound, inhibits LPS-induced activation of microglia," Biochemical and Biophysical Research Communications, vol. 418, no. 1, pp. 22-26, 2012.
132. S. Prokop, K. R. Miller, and F. L. Heppner, "Microglia actions in Alzheimer's disease," Acta Neuropathologica, vol. 126, no. 4, pp. 461-477, 2013.
133. M. Verri, O. Pastoris, M. Dossena et al., "Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease," International Journal of Immunopathology and Pharmacology, vol. 25, no. 2, pp. 345-353, 2012.
134. D. Ito, Y. Imai, K. Ohsawa, K. Nakajima, Y. Fukuuchi, and S. Kohsaka, "Microglia-specific localisation of a novel calcium binding protein, Iba1," Molecular Brain Research, vol. 57, no. 1, pp. 1-9, 1998.
135. A. Kuhlmann and C. Röhl, "Phenolic antioxidant compounds produced by in vitro. Cultures of Rosemary (Rosmarinus officinalis.) and their anti-inflammatory effect on lipopoly-saccharide-activated microglia," Pharmaceutical Biology, vol. 44, no. 6, pp. 401-410, 2006.
136. H. Braak, R. A. I. de Vos, E. N. H. Jansen, H. Bratzke, and E. Braak, "Neuropathological hallmarks of Alzheimer's and Parkinson's diseases," Progress in Brain Research, vol. 117, pp. 267- 285, 1998.
137. R. A. Armstrong, "The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease," Folia Neuropathologica, vol. 47, no. 4, pp. 289-299, 2009.
138. A. Serrano-Pozo, M. P. Frosch, E. Masliah, and B. T. Hyman, "Neuropathological alterations in Alzheimer disease," Cold Spring Harbor Perspectives in Medicine, vol. 1, no. 1, Article ID a006189, 2011.
139. E. Portelius, N. Mattsson, U. Andreasson, K. Blennow, and H. Zetterberg, "Novel abeta isoforms in Alzheimer's disease-their role in diagnosis and treatment," Current Pharmaceutical Design, vol. 17, no. 25, pp. 2594-2602, 2011.
140. R. Perneczky, P. Alexopoulos, and A. Kurz, "Soluble amyloid precursor proteins and secretases as alzheimer's disease biomarkers," Trends in Molecular Medicine, vol. 20, no. 1, pp. 8-15, 2014.
141. C. Haass, "Take five-BACE and the γ-secretase quartet conduct Alzheimer's amyloid beta-peptide generation," The EMBO Journal, vol. 23, no. 3, pp. 483-488, 2004.
142. T. Guo and D. W. Hobbs, "Development of BACE1 inhibitors for Alzheimer's disease," Current Medicinal Chemistry, vol. 13, no.15, pp. 1811-1829, 2006.
143. P. Meng, H. Yoshida, T. Matsumiya et al., "Carnosic acid suppresses the production of amyloid-β 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells," Neuroscience Research, vol. 75, no. 2, pp. 94-102, 2013.
144. H. Yoshida, P. Meng, T. Matsumiya et al., "Carnosic acid suppresses the production of amyloid-β 1-42 and 1-43 by inducing an α-secretase TACE/ADAM17 in U373MG human astrocytoma cells," Neuroscience Research, vol. 79, no. 1, pp. 83-93, 2014.
145. K. N. Dahlgren, A. M. Manelli, W. Blaine Stine Jr., L. K. Baker, G. A. Krafft, and M. J. Ladu, "Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability," The Journal of Biological Chemistry, vol. 277, no. 35, pp. 32046-32053, 2002.
146. D. M. Hartley, D. M. Walsh, C. P. Ye et al., "Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons," The Journal of Neuroscience, vol. 19, no. 20, pp. 8876-8884, 1999.
147. M. Hoshi, M. Sato, S. Matsumoto et al., "Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β," Proceedings of the National Academy of Sciences of the United States of America,vol. 100, no. 11, pp. 6370-6375, 2003.
148. R. Kayed, E. Head, J. L. Thompson et al., "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis," Science, vol. 300, no. 5618, pp. 486-489, 2003.
149. 1 - 42 are potent central nervous system neurotoxins," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6448-6453, 1998.
150. K. Ishii, W. E. Klunk, S. Arawaka et al., "Chrysamine G and itsderivative reduce amyloid β-induced neurotoxicity in mice," Neuroscience Letters, vol. 333, no. 1, pp. 5-8, 2002.
151. C. Adessi, M.-J. Frossard, C. Boissard et al., "Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease," The Journal of Biological Chemistry, vol. 278, no. 16, pp. 13905-13911, 2003.
152. D. J. Gordon, R. Tappe, and S. C. Meredith, "Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Aβ1-40 fibrillogenesis," Journal of Peptide Research, vol. 60, no. 1, pp. 37-55, 2002.
153. L. O. Tjernberg, J. Näslundt, F. Lindqvist et al., "Arrest of βamyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, vol. 271, no. 15, pp. 8545-8548, 1996.
154. L. O. Tjernberg, C. Lilliehöök, D. J. E. Callaway et al., "Controlling amyloid β-peptide fibril formation with protease-stable ligands," Journal of Biological Chemistry, vol. 272, no. 19, pp. 12601-12605, 1997.
155. C. Soto, E. M. Sigurdsson, L. Morelli, R. A. Kumar, E. M. Castaño, and B. Frangione, "β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy," Nature Medicine, vol. 4, no. 7, pp. 822- 826, 1998.
156. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada, "Curcumin has potent anti-amiloidogenic effects for Alzheimer's β-amyloid fibrils in vitro," Journal of Neuroscience Research, vol. 75, no. 6, pp. 742-750, 2004.
157. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada, "Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro," Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1690, no. 3, pp. 193-202, 2004.
158. K. Ono, K. Hasegawa, Y. Yoshiike, A. Takashima, M. Yamada, and H. Naiki, "Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's β-amyloid fibrils in vitro," Journal of Neurochemistry, vol. 81, no. 3, pp. 434-440, 2002.
159. T.Tomiyama,S.Asano,Y.Suwa et al., "Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro," Biochemical and Biophysical Research Communications, vol. 204, no. 1, pp. 76-83, 1994.
160. T. Thomas, T. G. Nadackal, and K. Thomas, "Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation," NeuroReport, vol. 12, no. 15, pp. 3263-3267, 2001.
161. N. Azad, H. Rasoolijazi, M. T. Joghataie, and S. Soleimani, "Neuroprotective effects of Carnosic acid in an experimental model of Alzheimer's disease in rats," Cell Journal, vol. 13, no. 1, pp. 39-44, 2011.
162. H. Rasoolijazi, N. Azad, M. T. Joghataei, M. Kerdari, F. Nikbakht, and M. Soleimani, "The protective role of carnosic acid against beta-amyloid toxicity in rats," The Scientific World Journal, vol. 2013, Article ID 917082, 5 pages, 2013.
163. C. J. Maynard, A. I. Bush, C. L. Masters, R. Cappai, and Q.-X. Li, "Metals and amyloid-β in Alzheimer's disease," International Journal of Experimental Pathology, vol. 86, no. 3, pp. 147-159, 2005.
164. J. A. Duce, A. I. Bush, and P. A. Adlard, "Role of Amyloid-β-metal Interactions in Alzheimer's Disease," Future Neurology, vol. 6, no. 5, pp. 641-659, 2011.
165. P. Faller, C. Hureau, and O. Berthoumieu, "Role of metal ions in the self-assembly of the Alzheimer's amyloid-β peptide," Inorganic Chemistry, vol. 52, no. 21, pp. 12193-12206, 2013.
166. F. Hane and Z. Leonenko, "Effect of metals on kinetic pathways of amyloid-β aggregation," Biomolecules, vol. 4, no. 1, pp. 101-116, 2014.
167. G. K. Gouras and M. F. Beal, "Metal chelator decreases Alzheimer β-amyloid plaques," Neuron, vol. 30, no. 3, pp.641-642, 2001.
168. M. P. Cuajungco, L. E. Goldstein, A. Nunomura et al., "Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc," The Journal of Biological Chemistry, vol. 275, no. 26, pp. 19439-19442, 2000.
169. V. Tõugu, A. Tiiman, and P. Palumaa, "Interactions of Zn(II) and Cu(II) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity," Metallomics, vol. 3, no. 3, pp. 250-261, 2011.
170. K. Ono, T. Hamaguchi, H. Naiki, and M. Yamada, "Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease," Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1762, no. 6, pp. 575-586, 2006.
171. R. T. Bartus, R. L. Dean III, B. Beer, and A. S. Lippa, "The cholinergic hypothesis of geriatric memory dysfunction," Science, vol. 217, no. 4558, pp. 408-414, 1982.
172. K. Blennow, M. J. de Leon, and H. Zetterberg, "Alzheimer's disease," The Lancet, vol. 368, no. 9533, pp. 387-403, 2006.
173. J. T. Coyle, D. L. Price, and M. R. De Long, "Alzheimer's disease: a disorder of cortical cholinergic innervation," Science, vol. 219, no. 4589, pp. 1184-1190, 1983.
174. E. Giacobini, "Cholinesterases: new roles in brain function and in Alzheimer's disease," Neurochemical Research, vol. 28, no. 3-4, pp. 515-522, 2003.
175. D. A. Casey, D. Antimisiaris, and J. O'Brien, "Drugs for Alzheimer's disease: are they effective?" Pharmacy and Therpeutics, vol. 35, no. 4, pp. 208-211, 2010.
176. D. Szwajgier, "Anticholinesterase activity of phenolic acids and their derivatives," Zeitschrift für Naturforschung C, vol. 68, no. 3-4, pp. 125-132, 2013.
177. M. Merad, W. Soufi, S. Ghalem et al., "Molecular interaction of acetylcholinesterase with carnosic acid derivatives: a neuroinformatics study," CNS & Neurological Disorders - Drug Targets, vol. 13, no. 3, pp. 440-446, 2014.
178. J.-H. Chen, H.-P. Ou, C.-Y. Lin et al., "Carnosic acid prevents 6-hydroxydopamine-induced cell death in SH-SY5Y cells via mediation of glutathione synthesis," Chemical Research in Toxicology, vol. 25, no. 9, pp. 1893-1901, 2012.
179. C.-R. Wu, C.-W. Tsai, S.-W. Chang, C.-Y. Lin, L.-C. Huang, and C.-W. Tsai, "Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson's disease: involvement of antioxidative enzymes induction," Chemico-Biological Interactions, vol. 225, pp. 40-46, 2015.